Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted in India to evaluate safety and efficacy of orally administered IMA001 in sickle cell disease patients.
Imalia Launches French Pilot Study of IMA001 in Sickle Cell Disease: Focus on Safety, Tolerability, and Quality of Life
Imalia is conducting in France a second monocentric, prospective, open label pilot study in